Navigation Links
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
Date:5/26/2009

ailable full prescribing information for tapentadol at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/022304s000lbl_v2.pdf

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) is a wholly owned subsidiary of Johnson & Johnson, the world's most broadly based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. More information can be found at http://www.jnjpharmarnd.com/.

PriCara,(R) Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

PriCara,(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is a major health care company in the United States dedicated to the needs of primary care providers who serve a vital role on the frontline of medicine. For more information about the company, please visit www.PriCara.com.

Grunenthal

Grunenthal, a privately owned pharmaceutical company based in Aachen, Germany, discovered and started development of tapentadol. Grunenthal and J&JPRD have shared development responsibilities for tapentadol for acute and chronic pain conditions since the companies signed a licensing agreement for tapentadol in 2003.

Grunenthal licensed marketing rights to tapentadol to Ortho-McNeil-Janssen Pharmaceuticals, Inc. for the United States, Canada and Japan. Grunenthal maintains marketing rights in Europe and other parts o
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
2. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
3. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
4. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
5. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
8. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
9. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
10. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
11. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014  Luoxis Diagnostics, Inc., a subsidiary of ... that its academic collaborators will present several peer-reviewed ... its novel RedoxSYS Diagnostic System, a first-in-class platform ... in response to injury or illness.  A poster ... clinical marker will be presented by Christopher ...
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
(Date:10/20/2014)... DIEGO , Oct. 20, 2014  AnaptysBio, ... of therapeutic antibodies, today announced the appointment of ... Officer. Dr. Londei will lead the preclinical and ... "We are pleased to welcome Dr. ... Hamza Suria , President and Chief Executive Officer ...
Breaking Medicine Technology:Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... Conduct Conference Call on, December 10, 2007 to Discuss SNS-595 ... ... SOUTH SAN FRANCISCO, Calif., Nov. 29 Sunesis,Pharmaceuticals, Inc. (Nasdaq: ... announced that it,will present data on the company,s two lead product ...
... Raised Worldwide Awareness and Funds ... to Fight Aids, Tuberculosis and Malaria, SEATTLE, Nov. 28 ... and distributor, today announced,the successful conclusion of "Change Me," an ... their thoughts on how to make the,world a better place. ...
Cached Medicine Technology:Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology 3Getty Images Celebrates Conclusion of 'Change Me' Imagery Forum 2Getty Images Celebrates Conclusion of 'Change Me' Imagery Forum 3
(Date:10/20/2014)... With a mere 19 days to November ... brief fundraising stop at the  Law Offices of ... a debate last night with his opponent Gov. Rick ... first seven minutes because Crist had an electric fan ... in one word: "weird." , Before touching on his ...
(Date:10/20/2014)... New York, NY (PRWEB) October 20, 2014 ... City based non-profit organization that helps New Yorkers ... lasting, positive changes toward health, housing, recovery and ... who have transformed the local community through their ... Managing Director, Marc Shapses , has been ...
(Date:10/20/2014)... October 20, 2014 hc1.com today ... secure cloud solution that enables healthcare organizations of ... ultimate healthcare-specific customer relationship management (“CRM”) solution. , ... unique needs of the healthcare industry, the hc1 ... providers and patients by combining healthcare CRM, HIPAA-compliant ...
(Date:10/20/2014)... 20, 2014 My Clients Plus ( ... application. The new module enables easy administration and ... life-cycle quality care. , This application allows users such ... practice, attach a to-do item to a specific client, ... set up reoccurring reminders for follow-ups. It's designed ...
(Date:10/20/2014)... October 20, 2014 Myoderm ... as Assistant Director of their CentralSource ... managing the innovative turnkey drug sourcing, distribution, and ... brings over 12 years of industry experience, in ... at the peak of their international success to ...
Breaking Medicine News(10 mins):Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2
... Eat Right, Move More and ... Milk Their Diets, DENVER, June 5 ... fad diets -- which seem to go in and out of,fashion like shoulder ... remain overweight or obese., A new campaign crossing the country, the Campaign ...
... ATLANTA, June 5 Elekta, a world class ... selected to supply,multiple Elekta Synergy(R) digital linear accelerator ... next few years., The new Elekta Synergy ... Radiation Therapy (IGRT), which Mary Bird Perkins,(MBP) began ...
... Fever for an evening of celebration, INDIANAPOLIS, June 5 ... honored by the March of Dimes on June 7 at ... help families,with critically ill babies throughout the state and to ... For several years, Anthem has teamed up with the March ...
... Coalition warns patients about injections on vacation ... YORK, June 5 The Physicians Coalition,for ... worldwide of the dangers of accepting Botox(R), ... from unfamiliar physicians during,vacation, cruise or spa ...
... watching a small group of neurons that enable sexual maturity ... near the developing nose, to deep inside the brain. ... the zebrafish will help explain why some neurons don,t make ... sexually mature as a result. , "They can go ...
... University researcher Bess Dawson-Hughes, M.D., chaired the ... Foundation (NOF) Clinician,s Guide to Prevention and ... Guide incorporates the World Health Organization (WHO) ... tool expected to increase the identification of ...
Cached Medicine News:Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement 2Health News:Elekta and Mary Bird Perkins Cancer Center Sign Strategic Multi-Center Radiation Therapy Systems Agreement 3Health News:Anthem Blue Cross and Blue Shield Honored by March of Dimes 2Health News:Botox and Restylane Not A Destination or Spa Treatment 2Health News:Botox and Restylane Not A Destination or Spa Treatment 3Health News:Botox and Restylane Not A Destination or Spa Treatment 4Health News:Zebrafish enable scientists to study the migration of neurons that enable sexual maturity 2Health News:Zebrafish enable scientists to study the migration of neurons that enable sexual maturity 3Health News:Tufts researcher leads revision of osteoporosis guidelines 2Health News:Tufts researcher leads revision of osteoporosis guidelines 3